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Making new ligands for a given protein by in situ
ligation of building blocks (or fragments) is an attrac-
tive method. However, it suffers from inherent limi-
tations, such as the limited number of available
chemical reactions and the low information content
of usual chemical library deconvolution. Here, we
describe a focused screening of adenosine deriva-
tives using X-ray crystallography. We discovered
an unexpected and biocompatible chemical reac-
tivity and have simultaneously identified the mode
of binding of the resulting products. We observed
that the NAD kinase from Listeria monocytogenes
(LmNADK1) can promote amide formation between
50-amino-50-deoxyadenosine and carboxylic acid
groups. This unexpected reactivity allowed us to
bridge in situ two adenosine derivatives to fully
occupy the active NAD site. This guided the design
of a close analog showing micromolar inhibition of
two human pathogenic NAD kinases and potent
bactericidal activity against Staphylococcus aureus
in vitro.
INTRODUCTION
Methods for rapid design and synthesis of new ligands are
eagerly sought to battle pathogens and cure infectious diseases
(Fischbach and Walsh, 2009). Despite a vast repertoire of
methods, new and more efficient approaches are still necessary
to follow recent rise in antibiotic resistance.
Ancient medicinal formulae and natural extracts have long
been a reservoir for discovering efficient therapeutic molecules.Structure 20, 11In such cases, the targets are usually identified only after an
active compound is isolated and characterized. In contrast,
current drug discovery strategies focus on searches for mole-
cules that modulate the function of selected targets. Indeed,
the number of identified targets is rising thanks to huge data
made available from genome-wide projects. However, the
bottleneck remains in the discovery of efficient ligands as well
as their improvement and development into potential drugs
(Fischbach and Walsh, 2009; Hajduk and Greer, 2007).
Until recently, large efforts relied on the synthesis of millions
of compounds to be screened automatically in order to find
so-called ‘‘hits’’ to be validated and optimized further using
medicinal chemistry. A drawback in this approach is the neces-
sity for an efficient and miniaturized assay (Hajduk and Greer,
2007; Schulz and Hubbard, 2009). Furthermore, the size of
these libraries remains limited (at most, 107 chemical entities)
compared to the huge number of possible drugs (an estimated
1060 molecules).
Target-based virtual screening has evolved recently as an
efficient alternative, often exhibiting a higher hit rate (Villoutreix
et al., 2009). It relies on the knowledge of a three-dimensional
structure of the target. However, the available experimental
structure might not be the best representative of the actual
target structure under physiological conditions. In fact, due to
dynamic heterogeneity and conformational equilibrium, obtain-
ing the correct target structure may require cocrystallization
with an appropriate ligand, as exemplified by the famous Imati-
nib now used in the clinic (Schindler et al., 2000). This suggests
that experimental screening is still necessary not only to explore
the conformational space available for each target but also to
identify an initial ligand.
Meanwhile, fragment-based approaches are improving
rapidly thanks to advances in methods for screening libraries
of small chemical compounds (between 102 and 104 molecules).
This makes an exhaustive diversity search within the corre-
sponding chemical space (an estimated 107 molecules) more07–1117, June 6, 2012 ª2012 Elsevier Ltd All rights reserved 1107
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In Cristallo Screening and In Situ Ligand Bridgingtractable (Schulz and Hubbard, 2009). In this context, nuclear
magnetic resonance (NMR) and X-ray crystallography appear
highly appropriate as they can simultaneously identify weak
binders and provide valuable structural information. Subsequent
growth of the fragment ‘‘hits’’ into ‘‘leads’’ (and then into drug
candidates) relies mainly on classical medicinal chemistry,
although structural information is instrumental to guide optimiza-
tion. This rational approach has already produced new ligands
with affinity in the nanomolar range for several targets (Chessari
and Woodhead, 2009); furthermore, it can also deal with the
intrinsic flexibility of the targeted structure (Gill et al., 2005).
An alternative fragment-based approach makes use of
biocompatible chemical reactions to tether and/or link together
fragments (Schmidt and Rademann, 2009). This technique has
been performed mainly in solution and does not require prior
knowledge of the target structure. The deconvolution of combi-
natorial libraries is not trivial, and this has currently limited the
size of these libraries. Furthermore, this approach has also
been limited by the small number of bioorthogonal/biocompat-
ible reactions made available by the chemists, despite active
research in this area. Nevertheless, it can also give access to
micromolar or nanomolar ligands from libraries of fragments
containing reactive groups (Schmidt and Rademann, 2009).
It is surprising that structure-based fragment screening and
in situ chemistry have not been combined extensively, despite
a clear complementarity and a valid proof of concept (Congreve
et al., 2003). Furthermore, molecular targets of drugs have long
been viewed as static and inert structures and not as potential
catalysts of new in situ reactions. However, a seminal example
was provided by a so-called ‘‘epitaxial selection’’ coupled to
esterification of boronic derivatives with alcohol (Katz et al.,
1995). This suggests that additional chemical entities can be
used to grow new ligands on the surface of a target. Enhanced
combination of structure-based fragment selection and in situ
chemistry would open new paths to ligand design and synthesis.
In this context, we were interested in studying a therapeutic
target discovered by genomic analysis. The lack of information
regarding potential inhibitors was important for an unbiased
study. In such a case, the search for potential binders may
accompany the initial characterization of the newly found thera-
peutic target. The starting point for ligand selection or design
may rely, in part, on sequence similarities and/or functional
annotations. We applied this biology-driven strategy to NAD
kinases whose genes were recently discovered (Kawai et al.,
2000). These proteins belong to an original superfamily of
kinases with no known drug acting on them (Labesse et al.,
2002). Bacterial NAD kinases were selected as they represent
new therapeutic targets for antibiotic development. In our
case, we focused on the enzyme from a human pathogen, the
NAD kinase from the Gram-positive Listeria monocytogenes
(named LmNADK1). We have recently shown its particular
enzymatic mechanism and the mode of binding of its natural
substrate and product; NAD and NADP, respectively (Poncet-
Montange et al., 2007). These functional and structural data
showed that the active site is mainly composed of two subpock-
ets occupied by the adenosine and nicotinamide riboside moie-
ties (accordingly named subsites A and N, respectively).
Our previous study also led to the discovery of a micromolar
inhibitor of an NADK (Poncet-Montange et al., 2007): di-(50-thio-1108 Structure 20, 1107–1117, June 6, 2012 ª2012 Elsevier Ltd All ri50-deoxyadenosine) (DTA). It was obtained by cocrystallizing
LmNADK1with amillimolar fragment: 50-thioacetyl-50-deoxyade-
nosine (TAA). It is surprising that the latterwasdeacetylated in situ
and subsequently dimerized through disulphide bond formation.
The structure of the resulting inhibitor bound to LmNADK1
showed the perfect mimicry of adenosine with riboside-
nicotinamide in the subsite N. However, the disulphide bridge
connecting the two adenosine moities is rather labile, and this
prevented further in vivo evaluation. Therefore, a new strategy
of fragment linking was necessary to improve the inhibitory effi-
ciency as well as its stability in order to get access to cell assays.
Here, we report the screening by X-ray crystallography of
adenosine congeners using LmNADK1 crystals. Functionalized
adenosine congeners were designed, synthesized, and then
combined to derive a micromolar inhibitor. This compound
shows potent inhibition of in vitro growth of the human pathogen
Staphylococcus aureus. We discuss a possible means to ratio-
nally generalize this approach relying on a reverse use of mech-
anism-based ligand design.
RESULTS
Screening of Adenosine Congeners by Direct
Cocrystallization with LmNADK1
The cocrystallization of LmNADK1 with TAA and the resulting
complex of LmNADK1 with DTA have suggested that the active
site can accommodate adenosines bearing a small chemical
group at its 50 position. To better characterize the active site,
we tested 50-methylthio-, 50-bromo-, and 50-fluoro-50-deoxyade-
nosine derivatives (compounds numbered 1, 2, and 3, respec-
tively) (Figure 1). In addition, 50-O-propargyl, 50-N-propargyl,
50-azido, and 50-amino groups (compounds 4, 5, 6, and 7,
respectively) were taken into consideration as useful reactive
groups for biocompatible chemistry (for click chemistry and
reductive amination, respectively).
Only two compounds (1 and 4) among the seven congeners
tested gave rise to protein crystals. In both cases, LmNADK1
crystals were needle shaped. They appeared to be orthorhombic
and isomorphous with the previously described structures of
LmNADK in its bound state (Poncet-Montange et al., 2007).
The structure of LmNADK1 cocrystallized with compound 1
(also named MTA) and the 50-O-propargyl derivative (compound
4) were refined to resolutions of 1.97 A˚ and 2.03 A˚, respectively
(Table 1). In both cases, we observed that two molecules of
these adenosine derivatives bind in the active site. Each adopts
a conformation very similar to that of the equivalent molecule of
TAA. Thus, onemolecule of MTAmimics the adenosinemoiety of
NAD, in subsite A, while the second mimics the nicotinamide-
ribose, in subsite N (Figures 2A and 2B). Protein interactions
with the two riboses and nucleobases resemble that previously
described with DTA (Poncet-Montange et al., 2007). While, the
50 derivatization of compound 4 was not clearly visible, probably
due to weak interactions with the protein and high flexibility,
the electron densities of the 50 sulfur atoms are well defined
for the two bound molecules, although the attached methyl
groups appear rather mobile. The two sulfur atoms are 4.9 A˚
apart (instead of 2.0 A˚ in DTA) and appear attracted into
two small and hydrophobic subpockets. One thiomethyl group
makes van der Waals interactions with two hydrophobicghts reserved
Figure 1. Structures of Molecules 1–15 Used in This Study
Picture drawn with the software Chemdraw.
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In Cristallo Screening and In Situ Ligand Bridgingresidues: isoleucine I1870 and tyrosine Y1920 protruding from
a second monomer. The second thiomethyl group is in contact
with the side chains of leucine L49 and glycine G46. It also points
toward the C8 of the adenosine occupying the subsite A (with
a distance 50S-C8 of 4.5 A˚). This suggested a short way to
bridge an adenosine in subsite N with an adenine in subsite A.
Cocrystals of LmNADK1 with compound 4 were too fragile to
be used for subsequent soaking and screening. Conversely, the
cocrystallization with MTA provided us with crystals for rapid
soaking into preequilibrated crystallization drops containing
the desired ligands.
Screening of 50-Functionalized Adenosine Derivatives
by Soaking in LmNADK1 Crystals
The determination of the structure of LmNADK1 in complex
with the other 50 derivatives (compounds 2, 3, 6, and 7) was
attempted by soaking crystals of LmNADK1 grown in complex
with MTA.
Soaking with compound 7, which harbors a positively charged
amino group, led to an empty structure of LmNADK1. This
showed that the soaking procedure was sufficient to remove
MTA from the active site. The 50-bromo and 50-fluoro derivatives
of adenosine (compounds 2 and 3) showed only partial occupa-
tion of the active site potentially due to their negatively charged
halogen atom (data not shown). The structure of LmNADK1 coc-
rystallized with the 50-N-propargyl derivative (5) was refined to
a resolution of 1.97 A˚ (Table 1). Two molecules were also
observed in the active site in a configuration highly similar to
that previously observed for MTA or compound 4 (data not
shown). As in the case of the two previous compounds, the 50
substitution of the adenosine in the site N points toward theStructure 20, 11position 8 of the adenosine occupying the site A. A crystal of
LmNADK1 bound to MTA was also soaked with compound 6,
and the resulting structure was refined to a resolution of 2.01 A˚
(Table 1). It resembles that of LmNADK1 in complex with MTA
(or compound 4) as two molecules of 6 occupying the active
site (Figure 2C). The electron density was weak for one of the
azido group (subsite A), while the second one (subsite N) ap-
peared more clearly. The latter points toward the peptide plane
of the glycine G46 in the vicinity of the leucine L49, as does the
thiomethyl group of compound 1 (discussed earlier).
The structures of LmNADK1 bound to MTA, compounds 4
and 6, highlighted the short distance (5 A˚) between the substi-
tuant at the 50 position (protruding from subsite N) and the C8
position of the adenine moiety in the subsite A (Figure 2). A short
chemical link with few rotatable bonds was envisioned to link the
carbon 50 of an adenosine to the carbon 8 of a facing adenosine.
Compared to the 50-50 disulphide bridge observed in DTA,
a connection 50-8 would shunt one ribose moiety and provide
more interactions with the protein. In order to build such a link,
we engaged in the functionalization of adenosine at its position
C8 with an emphasis on possible hemisynthetic route and soft or
biocompatible chemistry. Bromination of purine at this position
was promising, as it is rather straightforward and allows further
derivatization by amine, alcohol, or thiol groups in rather mild
conditions (in water at room temperature) (Zappelli et al., 1976).
Screening of 8-Brominated Adenosine Derivatives
by Soaking in LmNADK1 Crystals
We first checked that the 8-bromo derivatization fits into the
subpocket composed of the hydrophobic leucine L49 and
the glycine G46 main chain in the subsite A and partially fills in07–1117, June 6, 2012 ª2012 Elsevier Ltd All rights reserved 1109
Table 1. Data Collection and Refinement Statistics for LmNADK1 Complexes
Wild-Type
LmNADK1-1 LmNADK1-4 LmNADK1-5 LmNADK1-6
Data collection
Space group I222 I222 I222 I222
Cell dimension 62.5, 75.6, 63.0, 75.2, 62.8, 75.7, 62.9, 74.0,
a, b, c (A˚) 118.8 118.5 118.6 118.4
No. molecules in a.u. 1 1 1 1
Beamline ID14-4 ID14-2 ID29 ID14-1
Wavelength (A˚) 0.975 0.933 0.979 0.934
Resolution (A˚) 43.76-1.97 (2.08-1.97) 63.50-2.03(2.14-2.03) 48.34-1.97(2.08-1.97) 62.75-2.01(2.12-2.01)
Rmerge (%)
a 5.8 (27.7) 4.7 (48.7) 3.8 (30.4) 4.9 (37.7)
I/sI 1 22.3 (4.9) 19.2 (2.2) 10.9 (2.4) 13.3 (2.3)
Completeness (%) 93.3 (100.0) 98.5 (91.2) 99.9 (99.9) 98.1 (94.0)
Redundancy 6.5 (6.5) 4.1 (3.0) 4.8 (4.9) 5.7 (5.6)
B-wilson (A˚2) 32.9 33.7 36.3 25.3
Refinement
Resolution (A˚) 1.97 2.03 1.97 2.01
No. reflections 18,947 18,250 20,294 18,378
Rwork/Rfree (%)
b,c 20.6 / 23.8 18.4 / 22.6 19.3 / 22.9 18.6 / 20.4
No. of protein atoms 2,147 2,085 2,101 2,080
No. of water molecules 113 128 103 91
Ligand type 2 x 1 2 x 4 2 x 5 2 x 6
B factors (A˚2)
Protein 35.3 37.6 42.8 36.9
Ligands 33.2 43.1 62.2 41.3
Water 40.7 43.7 46.4 39.1
Rmsdd
Bond lengths (A˚) 0.009 0.008 0.009 0.006
Bond angles () 1.158 1.098 0.925 0.840
PDB 3v7u 3v80 3v7y 3v7w
Values in parentheses refer to the outermost resolution shell. a.u., asymmetric units. Rmsd, root-mean-square deviation.
aRmerge = ShklSi_jIhkl,i  Iaverage,hklj/jShklSi_jIhkl,ij3100.
bRwork = ShkljFobs – Fcalcj/Shkl jFobsj3100.
cRfree is calculated in the same way on a subset of reflections that are not used in the refinement (5%).
dDeviation from ideal values.
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In Cristallo Screening and In Situ Ligand Bridgingthe gap leading to the facing 50 position to connect. The structure
of LmNADK1 bound to 50-azido-8-bromo-50-deoxyadenosine (8)
was obtained by protein crystal soaking and refined at a 2.48 A˚
resolution (Table 2). Two molecules are observed in the active
site (data not shown) with similar orientations of the nucleobases
and the ribose moieties compared to the previous crystal struc-
tures. Two strong electron densities corresponding to the
bromide atoms were observed. The 8-bromo groups appear to
participate to favorable interactions with the protein in both
subsites. As expected, the 8-bromo group of the adenosine in
subsite A is in close contacts with the main chain of G46 and
with the side chain of L49. In subsite N, new interactions are
observed between the halogen and the side chain of a proline
(P1320) protruding from a flexible loop in a second monomer
(data not shown). These additional interactions may explain the
positive impact of the 8-bromination observed for the diadeno-
sines linked by a disulphide bridge (Petrelli et al., 2009).1110 Structure 20, 1107–1117, June 6, 2012 ª2012 Elsevier Ltd All riWe have also tested crystal soaking with 50-amino-8-bromo-
50-deoxyadenosine (9) (Figure 1). The crystal structure of
LmNADK1 in complex with 9 was refined at a resolution of
2.34 A˚ (Table 2). It revealed some surprising variations from
that with 8. Two molecules of 9 were clearly recognized in the
active site, but one adopts a particular conformation (subsite
A) while the second shows an extra electron density at its 50
end (subsite N). In subsite A, the 50-amino group of the adenosine
congener 9 forms a salt bridge and a hydrogen bond with the
side chain of the catalytic aspartate D45. This new interaction
promotes a complete reorientation of the ribose moiety
compared to that previously observed. Unexpectedly, the
adenosine occupying the subsite N appeared to have reacted
with a citrate molecule, which is clearly visible in the electron
density (Figure 3A). Citrate was used as a crystallization salt at
a 220 mM concentration. According to the clear and continuous
electron density, an amide bond was formed by the reaction ofghts reserved
Figure 2. In Cristallo Screening
Crystal structures of adenosine derivatives bound to LmNADK1 active site: (A) MTA (1), (B) 50-O-propargyl-50-deoxyadenosine (4), and (C) 50-azido-50-deoxy-
adenosine (6). In all cases, two ligands occupy the active site. Views of the 2FoFc electron density map in the active site with the ligand molecule omitted in the
Fourier synthesis. Map is contoured at 1.0 s. The picture (and Figures 3 and 4) was generated by the program PYMOL (http://pymol.sourceforge.net).
Structure
In Cristallo Screening and In Situ Ligand Bridginga carboxylate group of the citrate with the 50-amino group of 9.
The orientation of the attached citrate appeared stabilized by
various interactions including van der Waals contacts with the
8-bromo atom. While the three carboxylate groups are clearly
identified in the electron density, the central hydroxyl group of
the citrate was poorly visible. Accordingly, the citryl adduct
may adopt alternating conformations (not modeled) that cannot
be differentiated at the current resolution.
These two additional crystal structures demonstrate that NAD
kinases can accommodate 8-bromo derivatization at both
subsites in their active site. The structure bound to the adduct
of 9, and citrate also highlighted the reactivity of the amino group
at the 50 position (in the subsite N).
In Situ Ligand Bridging to Form a New Diadenosine
Inhibitor
The constraints derived from the crystal structures of LmNADK1
bound to various adenosine derivatives suggested that a small
linker could be added to connect the position 8 to the position
50 of two adenosine congeners occupying subsites A and N,Structure 20, 11respectively. We attempted to bridge in situ 8 to 9 using
a small bifunctional linker. The required reactivity on the C8
side (subsite A) limited the choice to either an amino-, alcohol-,
or thiol-containing compound, with the latter being expected to
be the most reactive. The thiol group was a first-choice candi-
date due to the rather hydrophobic nature of the subpocket in
the vicinity of the C8 position. On the other side (50 position in
subsite N), an acidic (or aldehydic) group was expected to lead
to amidation (or amination) according to the aforementioned
results. Finally, thioglycolic acid (TGA) was envisioned as an
adequate linker. By combination with substitution of the 8-bromo
group, this was expected to provide a way to rapidly build new
diadenosines within the active site of the therapeutic target.
In situ bridging was attempted using our set of 8-bromo-
adenosine derivatives (8 and 9). Crystals were soaked into crys-
tallization drop containing the desired mixture of nucleosides
and TGA (9 + 9 + TGA or 8 + 9 + TGA). Our various attempts
led to the detection of the same adduct as discussed earlier,
which was due to the reaction of 9 with citrate (present at high
concentration in the crystallization buffer).07–1117, June 6, 2012 ª2012 Elsevier Ltd All rights reserved 1111
Table 2. Data Collection and Refinement Statistics for LmNADK1
Complexes
Wild type
LmNADK1-8
LmNADK1-
9-citrate
LmNADK1-
10-9
Data collection
Space group I222 I222 I222
Cell dimension 62.5, 75.7 63.1, 76.0 62.9, 75.6
a, b, c (A˚) 118.2 119.0 118.7
No. molecules
in a.u.
1 1 1
Beamline ID14-2 ID14-2 ID14-4
Wavelength (A˚) 0.933 0.933 1.04
Resolution (A˚) 55.30–2.48
(2.61–2.48)
64.02–2.51
(2.51–2.38)
63.76–2.29
(2.41–2.29)
Rmerge (%)
a 6.4 (48.7) 6.9 (50.8) 3.4 (31.8)
I/sI 14.6 (2.1) 18.6 (2.8) 16.6 (3.4)
Completeness (%) 98.5 (100.0) 97.7 (100.0) 99.2 (100.0)
Redundancy 3.3 (3.7) 4.5 (4.5) 4.8 (5.4)
B-wilson 49.6 44.8 44.2
Refinement
Resolution (A˚) 2.48 2.38 2.29
No. reflections 10,105 12,094 12,686
Rwork/Rfree (%)
b,c 20.4/23.7 20.7/24.6 19.7/24.6
No. of protein
atoms
2,069 2,063 2,093
No. of water
molecules
76 81 117
Ligand type 2 3 8 9 + citryl-9 12
B factors (A˚2)
Protein 42.8 45.7 29.1
Ligands 46.2
(occ. 70%)
49.3 38,4
(occ. 80%)
Water 37.4 45.0 31.0
Rmsdd
Bond lengths (A˚) 0.004 0.005 0.004
Bond angles () 0.854 1.047 0.934
PDB 3v8m 3v8n 3v8p
Values in parentheses refer to the outermost resolution shell. a.u., asym-
metric units. Rmsd, root-mean-square deviation.
aRmerge = ShklSi_jIhkl,i  Iaverage,hklj/jShklSi_jIhkl,ij3100.
bRwork = ShkljFobs  Fcalcj/Shkl jFobsj3100.
cRfree is calculated in the same way on a subset of reflections that are not
used in the refinement (5%).
dDeviation from ideal values.
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In Cristallo Screening and In Situ Ligand BridgingThis prompted us to perform the thiolation using standard
chemistry while attempting in situ amidation. Soaking of such
an adenosine derivative (thioglycolated 8; named 10) in the pres-
ence of 9 led to the formation of a new chemical compound
(hereinafter named 12) (Figure 1). The corresponding structures
were refined to a 2.29 A˚ resolution (Table 2). It brought to light
the formation of a covalent link between the 50-amino end of
one adenosine (subsite N) and acidic group of the glycolic moiety
attached at the position 8 of the other adenosine (in subsite A).1112 Structure 20, 1107–1117, June 6, 2012 ª2012 Elsevier Ltd All riA continuous electron density was clearly visible as illustrated
for the mixture containing 10 and 9 (Figure 3B). As expected,
the sulfur atom was in contact with G46 and L49. Conversely,
very few interactions were observed with the newly formed
amide group and the protein. In agreement, the oxygen atom
of the carbonyl group was not clearly visible in the electron
density of the refined structure, which may correspond to
multiple orientations. The positions of the adenine rings were
nearly identical to our previous crystal structures of bound
LmNADK1, and the active site structure was apparently affected
little by the covalent connection formed between the two aden-
osine derivatives (Figure 3B).
The formation of this bridge confirmed the propensity of
LmNADK1 to promote amidation at the 50 amino end of an aden-
osine occupying the subsite N.
Role of H223 in Amidation Catalysis
The in situ formation of the amide bond is reminiscent to the
removal of the 50-thioacetyl group of TAA by the same enzyme
(Poncet-Montange et al., 2007). These two unexpected activities
can be rationalized by analysis of the crystal structures of
LmNADK1 complexed with NAD, NADP, and a product mimic,
20-phospho-diadenosine diphosphate (Poncet-Montange et al.,
2007). The histidine H223 is hydrogen bonded to a 50-phosphate
group in most of these structures (Figure 4). This polar residue is
the only side chain that transiently interacts with the phosphate
group from the adenosine in subsite N (Poncet-Montange
et al., 2007). Accordingly, we propose that H223 in LmNADK1
stabilizes the tetragonal intermediate of the amidation and
deacetylation reactions.
In order to test this hypothesis, we substituted a glutamate for
the histidine. The mutated enzyme H223E was cocrystallized
with MTA in the same conditions as previously described for
the complex of this mutant with TAA (Protein Data Bank [PDB]
2Q5F). It adopts a very similar structure beside the reorientation
of the mutated residue that gets buried outside the active site
(Poncet-Montange et al., 2007). We then soaked a crystal of
this mutant with 50-amino-8-bromo-50-deoxyadenosine (9), and
we observed two unreacted molecules of 9 in the structure, no
covalent attachment of a citrate molecule could be detected
(Figure 3C and Table 3). We also soaked another crystal of the
mutant H223E with 50-amino-50-deoxyadenosine (7) and solved
the structure at a 2.37 A˚ resolution (Table 3). While this
compound does not bind to the crystallized wild-type enzyme,
it occupies the site N in themutant formwhile a glycerol molecule
occupies the site A. However, aswith 9, we observed no covalent
attachment of citrate or other acidic compound (data not shown).
Chemical Synthesis
While X-ray crystallography was efficient in detecting the
product formed in situ, attempts to extract and purify the novel
adduct (named 12) with a 50(N),8(C) amide link from the protein
crystals have failed so far. Thus, the chemical synthesis of
compound 12, as well as the related diadenosine derivatives
13, 14, and 15 (Figure 1), was performed. Briefly, compounds
12 and 13 were obtained by PyBOP-mediated coupling of the
8-TGA adenosine derivatives (10 or 20) and the 50-amino adeno-
sine derivatives (17 or 19), followed by complete deprotection of
intermediate products (21 or 22) (see Supplemental Information).ghts reserved
Figure 3. In Situ Amidation
Crystal structures of LmNADK1 active site in complex with products of in situ chemistry detected in thewild-type enzyme or the unreacted precursors observed in
the mutant LmNADK1-H223E. (A) 8-bromo-50-amino-50-deoxyadenosine (9) with covalently linked citrate in subsite N or unreacted in subsite A, (B) 8-bromo-
50-amino-50-deoxyadenosine (9) covalently linked in situ with 8-thioglycolic-50-azido-50-deoxyadenosine (10), and (C) 8-bromo-50-amino-50-deoxyadenosine (9)
unreacted after soaking in the crystals of the mutated LmNADK1-H223E.
Structure
In Cristallo Screening and In Situ Ligand BridgingCompounds 14 and 15were obtained by Staudinger reduction of
the corresponding 50-azido derivatives 12 and 13 in high yield
after purification by reverse phase high-performance liquid chro-
matography (HPLC).
Biological Activity
The inhibitory potencies of compounds 12–15 were evaluated
in vitro against two purified NAD kinases (LmNADK1 and
SaNADK). Most showed little inhibition (up to 30%) of NADK,
even at high concentrations (up to 0.5 mM). Only compound
15 exhibited significant activity, with a Ki value of 25 ± 5 mM
against LmNADK1 and 50 ± 5 mM against SaNADK. Com-
pound 15 was assayed for bactericidal activity against
L. monocytogenes and a human pathogenic strain of S. aureus
(S25 strain). The NADK inhibitor showed little activity on
L. monocytogenes in the tested conditions but had a significant
bactericidal activity at 1 mg/ml against S. aureus. Survival ofStructure 20, 11S. aureus is shown as a function of NADK inhibitor concentra-
tions (Figure 5). However, increasing the concentration of the
inhibitor did not lead to any increase in bactericidal activity
potentially due to a saturation of the access to the target within
the bacteria or a low solubility at high concentrations in condition
tested. Nevertheless, its efficiency compares favorably with that
of reference compounds such as vancomycin (8 mg/ml) (Rouse
et al., 2007). In parallel, its cytotoxicity was assayed on HeLa
cells in culture for 96 hr. No change in cell shape and multiplica-
tion rate was observed when tested at 10 mM. Similarly, no cyto-
toxicity could be detected on human fetal lung fibroblast (MRC-5)
cells for the compounds 13 and 15 at 10 mM and 100 mM.
Accordingly, the new compound 15 represents a new lead that
expands the repertoire of inhibitors showing high-potency
affinity against the staphylococcal pathogen. Further evaluation
will be necessary to verify the entrance of this compound in the
bacterial cells and to confirm its true target in vivo.07–1117, June 6, 2012 ª2012 Elsevier Ltd All rights reserved 1113
Figure 4. Crystal Structure Comparison and Catalytic Mechanism
Structural comparison of 20-phospho-AppA bound to LmNADK1 (PDB 2i2e;
shown as sticks with green carbons) and the amidation product formed in situ
(this study; shown as sticks with gray carbons). For clarity, only the side chain
of the two catalytic residues is indicated. The side chain of histidine H223 is
hydrogen bonded to a phosphate group of the diphosphate-diadenosine,
a substrate mimic of NAD kinases. Distances (in angstroms) are shown in violet
(crystal structure of LmNADK1-20-phosphoAppA) and dark blue (combined
model of the conformation of H223 to catalyze amide bond formation).
Table 3. Data Collection and Refinement Statistics for
LmNADK1-(H223E) Complexes
H223E
LmNADK1-7 LmNADK1-9
Data collection
Space group I222 I222
Cell dimension
a, b, c (A˚) 63.1, 75.0, 118.6 62.7, 77.1, 118.3
No. molecules (a.u.) 1 1
Beamline ID14-1 ID14-1
Wavelength (A˚) 0.933 0.933
Resolution (A˚) 63.37-2.37
(2.50-2.37)
64.62-2.39
(2.52-2.39)
Rmerge (%)
a 6.8 (48.6) 6.3 (43.3)
I/sI 14.6 (2.4) 15.5 (2.7)
Completeness (%) 100.0 (100.0) 96.1 (99.8)
Redundancy 3.7 (3.8) 4.3 (4.4)
B-wilson (A˚2) 36.9 35.3
Refinement
Resolution (A˚) 2.37 2.39
No. reflections 11,807 11,205
Rwork/Rfree (%)
b,c 20.6/25.1 19.5/26.4
No. of protein atoms 2,075 2,071
No. of water molecules 106 101
Ligand type 7 (site N) 2 3 9
B factors (A˚2)
Protein 42.2 40.0
Ligand 38.4 (occ. 80%) 46.6
Water 43.6 40.8
Rmsdd
Bond lengths (A˚) 0.002 0.003
Bond angles () 0.574 0.777
PDB 3v8q 3v8r
Values in parentheses refer to the outermost resolution shell. a.u., asym-
metric units. Rmsd, root-mean-square deviation.
aRmerge = ShklSi_jIhkl,i – Iaverage,hklj/jShklSi_jIhkl,ij3100.
bRwork = ShkljFobs – Fcalcj/Shkl jFobsj3100.
cRfree is calculated in the same way on a subset of reflections that are not
used in the refinement (5%).
dDeviation from ideal values.
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The discovery of new antibacterial compounds is urgently
required and highly challenging. Structure-based drug design
is a promising method, but antibacterial compounds success-
fully built using this method are still awaited (Simmons et al.,
2010). Its combination with in situ chemistry is still in its infancy,
with very few examples described so far (Congreve et al., 2003;
Poncet-Montange et al., 2007; Scott et al., 2009). Indeed, most
of these applications relied on forming disulphide bridges. This
labile bonds prevent further in vivo evaluation of the derived
compounds.
Here, we extend the repertoire of biocompatible chemical
reaction and build a compound within the active site of
LmNADK1, which emerges as a promising therapeutic target.
The resulting dinucleoside inhibits bacterial NAD kinases that
catalyze an essential biochemical reaction not targeted by
current antibiotics. The new chemical entity represents a signifi-
cant improvement as it is the first one made available to probe
the role of NAD kinases in vivo. The new chemical compound
showed promising antistaphylococcal activity in vitro. Further
analyses are required to confirm its mechanism of action, but
its observed activity on leaving bacteria and its apparently low
toxicity on human cells is highly encouraging.
The in situ amidation we observed corresponds to the reaction
of a small acidic compound (citrate) and a 50-amino-50-deoxya-
denosine bound into the active site. It is surprising that this ami-1114 Structure 20, 1107–1117, June 6, 2012 ª2012 Elsevier Ltd All ridation occurs without prior activation of the acidic moiety, while
this is required for all amidationsperformedbybiological systems
described so far (Funabashi et al., 2010). The reaction seems to
be catalyzed by the protein as a pointmutation (H223E) abolishes
the reaction. The crystal structures of LmNADK1 in complex with
various dinucleotides (Poncet-Montange et al., 2007) suggest
a mechanism for the observed reactivity of the 50-amino group
of adenosine occupying the subsite N. A similar conclusion can
be drawn for the deacetylation of TAA previously described to
occur at the same position (Poncet-Montange et al., 2007).
Indeed, both reactions possess a similar tetragonal intermediate
that can be mimicked by a phosphate group. The proposed
mechanism of amidation/deacetylation suggests a possible
generalization to other nucleotide-binding proteins as soon asghts reserved
Figure 5. Antibacterial Effect of NADK Inhibitor on S. aureus
Suspensions (100 ml) of S. aureus corresponding to 2.103 bacteria were
incubated overnight at 37C with increasing concentrations of inhibitor (1 to
100 mg/ml). Percent bacterial killing was determined as the ratio of colony-
forming units after incubation with inhibitor to that of colony-forming units
after incubation with buffer alone. Data are mean values ± SD from three
separate experiments. *p < 0.05, Student’s t test.
Structure
In Cristallo Screening and In Situ Ligand Bridginga histidine residue can be brought into the vicinity a phosphate
group from a bound ligand.
Here, we have shown the possible use of a protein to build up
its new ligands following a focused screening by X-ray crystal-
lography. This example illustrates the potential of biology-driven
fragment-based drug design, where both protein characteriza-
tion and ligand screening are guided by means of X-ray
crystallography.
EXPERIMENTAL PROCEDURES
Cloning, Expression, Purification, and Activity Assay of NADKinases
The NAD kinase 1 (EC 2.7.1.23) coding sequence was amplified by the PCR
method from the genomic DNA isolated from Staphylococcus aureus strain
COL by using Phusion DNA polymerase, dNTPs, and the following 50- and
30-primers: 50-Sa, 50-GGAATTCCATATGCGTTATACAATTTTAACTAAAGGT-
30, and 30-Sa2, 50-CGGCGCCTCGAGTCGTTCTTCATCACTTGATATG-30.
The amplified DNA was cloned into the expression vector pET22b (Novagen)
at the NdeI and XhoI restriction sites (underlined), giving the plasmid
pLA19.3.4, which was sequenced to verify its integrity. The plasmid
pLA19.3.4 was then used to express Staphylococcus aureus NAD kinase
with a Hexahistidine tag at its C terminus in Escherichia coli. His-tagged
LmNADK1 (wild-type and variant H223E) and SaNADK were expressed in
E. coli and purified on cobalt-based IMAC resins (Clontech) as previously pub-
lished (Poncet-Montange et al., 2007). LmNADK1 and SaNADK were dialyzed
against buffer 50 mMNaH2PO4 and 100 mMNaCl, pH 7.5 and pH 8.5, respec-
tively, and stored at 4C.
The NAD kinase activity was determined by measuring the absorbance at
340 nm to follow the formation of reduced NADP produced by a coupling
enzyme (glucose-6-phosphate dehydrogenase from yeast). This enzyme and
its substrate were purchased from Sigma-Aldrich. The assay was performed
in a 0.5 ml sample of 50 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 2 mM sodium
citrate, 1 mM glucose-6-phosphate at 30C using a spectrophotometer
(Eppendorf ECOM 6122). Increasing concentrations of inhibitors were tested
at three NAD concentrations (0.2, 0.5, and 1 mM) in the presence of 4 mM
or 2 mM ATP for LmNADK1 and SaNADK, respectively. Dixon plots were
used to determine Ki. Half-inhibitory concentrations (IC50) were determined,
in the presence of 1 mM NAD and 4 mM ATP or 2 mM ATP, depending on
the enzyme. Data are mean values (±SD) from two separate experiments.
We also checked that the inhibitors had no effect on the coupling enzyme
activity.Structure 20, 11Chemical Synthesis
MTA (1) was purchased from Sigma-Aldrich Data. The detailed protocol for
syntheses of compounds 2–15 are given in the Supplemental Information.
Briefly, 50-bromo-50-deoxyadenosine (2), 50-fluoro-50-deoxyadenosine (3),
and 50-O-propargylamino-50-deoxyadenosine (4) were prepared as previously
described with minor modifications (for references, see the Supplemental
Information). 50-Amino-50-deoxyadenosine (7) was obtained by catalytic hydro-
genation of 50-azido-50-deoxyadenosine (6), and 50-azido-8-bromo-50-deoxya-
denosine (8) was obtained by bromination of 6 using NBS in DMF. 50-Azido-8-
carboxymethylthio-50-deoxyadenosine (10) was obtained by reacting 8 and
TGA in the presence of NaH in DMF. The Staudinger reduction of 50-azides 8
and 10 yielded the 50-amino derivatives 9 and 11, respectively. Compounds
12 and 13were obtained byPyBOP-mediated coupling of the 8-TGAadenosine
derivatives (10 or 20,30-O-isopopylidene protected 20) and the 50-amino adeno-
sine derivatives 7 or 9modifiedwith a 20,30-O-isopopylidene protection (named
17 or 19), followed by complete deprotection of intermediate products (21 and
22; see Scheme in Supplemental Experimental Procedures). Compounds 14
and15weresubsequently obtainedbyStaudinger reduction of thecorrespond-
ing 50-azidoderivatives 12 and 13. The structures of all synthesized compounds
were confirmed by high resolutionmass spectrometry andNMRspectra. Purity
was checked by C18 reverse phase HPLC and was up to 98%.
Crystallization
First, we have optimized the crystallization process by screening around the
previously described conditions. PEG400 was kept as the major precipitant
while salts and additives were varied. Our goal was to grow crystals in condi-
tions providing cryoprotection to ease crystal handling while setting up a ligand
screening by crystallography. Compared with MPD or hexanediol, glycerol
appeared the best additive, although the maximum acceptable concentration
was around 6%. Potassium citrate and sodium bromide appeared important to
reproduce best diffracting crystals. The pH was kept acidic (range = 4.9–5.1),
and a dedicated crystallization kit (24 conditions) was set up to ensure repro-
ducibility from one protein sample to another. Crystals were grown by mixing
1 ml of the protein solution concentrated at 9 mg/ml and complexed with 1with
an equal volume of crystallization buffer (30 mM sodium bromide, 220 mM
potassium citrate, pH 4.8–5.1, 6% glycerol, 15%–16%w/v polyethylene glycol
400), equilibrated over 0.5 ml of the same buffer. As previously, the complexes
with bound ligandmimics were solved using crystals in the orthorhombic form.
After growing them in the presence of 1, crystals were washed in the mother
liquor and soaked with a millimolar concentration of the desired ligand in a
preequilibrate hanging drop.
Crystallographic Studies
X-ray diffraction data sets were collected from single crystals frozen in liquid
nitrogen at the European Synchrotron Radiation Facility (ESRF; Grenoble,
France; beamlines ID14-1, ID14-2, ID14-4, and ID29). Images were processed
using the program MOSFLM (Leslie, 2006), and the intensities were merged
using SCALA (Evans, 2006) and TRUNCATE from the CCP4 program suite
(Collaborative Computational Project, Number 4, 1994; see Tables 1, 2, and
3). X-ray structures were solved by isomorphous replacement using previously
solved structures (Poncet-Montange et al., 2007). Refinement was performed
by alternating manual building using COOT (Emsley et al., 2010) and energy
minimization (with TLS optimization) using REFMAC5 (Murshudov et al.,
2011) and/or PHENIX (Adams et al., 2010).
As in the case of the former structures, some side chains and several
short segments of the protein (mainly loops 69-TGHL-72, 91-AKGE-94,
110-GIGKK-114, and, less frequently, 129-SGGP-132) were not clearly visible
in most electron density maps or showed alternating configurations. Some of
these residues as well as a few mobile side chains were modeled with partial
occupancies. Similarly, partial occupancies of mobile moieties in the ligands
(e.g., terminal azidoorpropargyl groups)or labilebromineatomswereoptimized
while keeping the corresponding B factors to reasonable values (according to
the B factors of connected or neighboring atoms and that of the whole ligand).
In all cases, crystal structure quality was validated using mainly tools
made available in COOT (e.g., Ramachandran plot, density fit analysis) and
in CCP4 (SFCHECK and PROCHECK). The global G factor was always positive
(range = 0.08–0.19). According to the Ramachandran plot, a small set of
common outliers were present in most or all of these structures. This includes07–1117, June 6, 2012 ª2012 Elsevier Ltd All rights reserved 1115
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In Cristallo Screening and In Situ Ligand Bridgingalanine A162, glycinesG43 andG130, and glutamate E263. In all the structures
solved, the electron density was clear for the residues G43 and A162, which
are two conserved residues buried in the active site. Their conformation is
very well defined in all the structures of LmNADK1 solved so far. Conversely,
G130 belongs to a flexible loop with a locally weak electron density due to
alternating conformation. Similarly, E263 may exist in alternating confor-
mation, although only the major one can be modeled. This glutamate is only
two residues ahead of the polyhistidine tag forming a highly mobile C-terminal
tail. Indeed, the affinity tag could not be modeled in most protein-ligand
complexes. Figures of ligands and corresponding electron density were
generated using PyMOL (http://pymol.sourceforge.net).
Bactericidal Activity Assay
TheStaphylococcusaureusS25strain, ahumanclinical isolate,wasgrownover-
night in brain heart infusion (BHI) broth at 200 rpm and 37C. Overnight cultures
were diluted to OD600nm = 0.05 in BHI-PBS (25% v/v). Bacteria were grown at
200 rpm and 37C until cultures reached OD600nm = 0.5. Bacterial suspensions
were adjusted to a concentration of 2.105 bacteria/ml. In amicrotiter plate, 2.103
bacteriawere incubated overnight at 200 rpmand37Cwith increasing concen-
trations of NADK inhibitor in 0.1 ml BHI-PBS (25% v/v) per well. To quantify the
bactericidal activity, each bacterial suspension was serially diluted in BHI and
plated on BHI agar plates in duplicates. Plates were incubated at 37C for
24 hr to 48 hr, and the number of colony forming units was determined.
Human Cell Cytotoxycity
The human cervical carcinoma HeLa cells were maintained in a humidified
atmosphere at 37C in 5%CO2 in 75 cm
2 plastic flasks in Dulbecco’sModified
Eagle Medium (DMEM; GIBCO) supplemented with 10% fetal bovine serum
(FBS; APP), 100 U/ml penicillin, and 10 mg/ml streptomycin. To evaluate the
cytotoxicity of the chemical compounds, HeLa cells were seeded in 96-well
plates at low density in presence of DMEM supplemented with 10% FBS
and treated with different compounds at 10 mM for 96 hr. The final concentra-
tion of DMSO in the culture medium was at 0.1% (v/v) to avoid toxicity of the
solvent. Cell shape and adherence were monitored and all assays were per-
formed in duplicate. DMSO was used as negative control.
The effect of the compounds 13 and 15 (dissolved in DMSO at different
concentrations), on the growth of MRC5 human cells was also carried out in
triplicate with the platform Imagif (Laboratoire de Cultures Cellulaires, ICSN,
CNRS, France).
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